Publications by authors named "Mohammad Jahani"

45 Publications

Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study.

Authors:
Spencer L James Chris D Castle Zachary V Dingels Jack T Fox Erin B Hamilton Zichen Liu Nicholas L S Roberts Dillon O Sylte Gregory J Bertolacci Matthew Cunningham Nathaniel J Henry Kate E LeGrand Ahmed Abdelalim Ibrahim Abdollahpour Rizwan Suliankatchi Abdulkader Aidin Abedi Kedir Hussein Abegaz Akine Eshete Abosetugn Abdelrahman I Abushouk Oladimeji M Adebayo Jose C Adsuar Shailesh M Advani Marcela Agudelo-Botero Tauseef Ahmad Muktar Beshir Ahmed Rushdia Ahmed Miloud Taki Eddine Aichour Fares Alahdab Fahad Mashhour Alanezi Niguse Meles Alema Biresaw Wassihun Alemu Suliman A Alghnam Beriwan Abdulqadir Ali Saqib Ali Cyrus Alinia Vahid Alipour Syed Mohamed Aljunid Amir Almasi-Hashiani Nihad A Almasri Khalid Altirkawi Yasser Sami Abdeldayem Amer Catalina Liliana Andrei Alireza Ansari-Moghaddam Carl Abelardo T Antonio Davood Anvari Seth Christopher Yaw Appiah Jalal Arabloo Morteza Arab-Zozani Zohreh Arefi Olatunde Aremu Filippo Ariani Amit Arora Malke Asaad Beatriz Paulina Ayala Quintanilla Getinet Ayano Martin Amogre Ayanore Ghasem Azarian Alaa Badawi Ashish D Badiye Atif Amin Baig Mohan Bairwa Ahad Bakhtiari Arun Balachandran Maciej Banach Srikanta K Banerjee Palash Chandra Banik Amrit Banstola Suzanne Lyn Barker-Collo Till Winfried Bärnighausen Akbar Barzegar Mohsen Bayati Shahrzad Bazargan-Hejazi Neeraj Bedi Masoud Behzadifar Habte Belete Derrick A Bennett Isabela M Bensenor Kidanemaryam Berhe Akshaya Srikanth Bhagavathula Pankaj Bhardwaj Anusha Ganapati Bhat Krittika Bhattacharyya Zulfiqar A Bhutta Sadia Bibi Ali Bijani Archith Boloor Guilherme Borges Rohan Borschmann Antonio Maria Borzì Soufiane Boufous Dejana Braithwaite Nikolay Ivanovich Briko Traolach Brugha Shyam S Budhathoki Josip Car Rosario Cárdenas Félix Carvalho João Mauricio Castaldelli-Maia Carlos A Castañeda-Orjuela Giulio Castelpietra Ferrán Catalá-López Ester Cerin Joht S Chandan Jens Robert Chapman Vijay Kumar Chattu Soosanna Kumary Chattu Irini Chatziralli Neha Chaudhary Daniel Youngwhan Cho Jee-Young J Choi Mohiuddin Ahsanul Kabir Chowdhury Devasahayam J Christopher Dinh-Toi Chu Flavia M Cicuttini João M Coelho Vera M Costa Saad M A Dahlawi Ahmad Daryani Claudio Alberto Dávila-Cervantes Diego De Leo Feleke Mekonnen Demeke Gebre Teklemariam Demoz Desalegn Getnet Demsie Kebede Deribe Rupak Desai Mostafa Dianati Nasab Diana Dias da Silva Zahra Sadat Dibaji Forooshani Hoa Thi Do Kerrie E Doyle Tim Robert Driscoll Eleonora Dubljanin Bereket Duko Adema Arielle Wilder Eagan Demelash Abewa Elemineh Shaimaa I El-Jaafary Ziad El-Khatib Christian Lycke Ellingsen Maysaa El Sayed Zaki Sharareh Eskandarieh Oghenowede Eyawo Pawan Sirwan Faris Andre Faro Farshad Farzadfar Seyed-Mohammad Fereshtehnejad Eduarda Fernandes Pietro Ferrara Florian Fischer Morenike Oluwatoyin Folayan Artem Alekseevich Fomenkov Masoud Foroutan Joel Msafiri Francis Richard Charles Franklin Takeshi Fukumoto Biniyam Sahiledengle Geberemariyam Hadush Gebremariam Ketema Bizuwork Gebremedhin Leake G Gebremeskel Gebreamlak Gebremedhn Gebremeskel Berhe Gebremichael Getnet Azeze Gedefaw Birhanu Geta Agegnehu Bante Getenet Mansour Ghafourifard Farhad Ghamari Reza Ghanei Gheshlagh Asadollah Gholamian Syed Amir Gilani Tiffany K Gill Amir Hossein Goudarzian Alessandra C Goulart Ayman Grada Michal Grivna Rafael Alves Guimarães Yuming Guo Gaurav Gupta Juanita A Haagsma Brian James Hall Randah R Hamadeh Samer Hamidi Demelash Woldeyohannes Handiso Josep Maria Haro Amir Hasanzadeh Shoaib Hassan Soheil Hassanipour Hadi Hassankhani Hamid Yimam Hassen Rasmus Havmoeller Delia Hendrie Fatemeh Heydarpour Martha Híjar Hung Chak Ho Chi Linh Hoang Michael K Hole Ramesh Holla Naznin Hossain Mehdi Hosseinzadeh Sorin Hostiuc Guoqing Hu Segun Emmanuel Ibitoye Olayinka Stephen Ilesanmi Leeberk Raja Inbaraj Seyed Sina Naghibi Irvani M Mofizul Islam Sheikh Mohammed Shariful Islam Rebecca Q Ivers Mohammad Ali Jahani Mihajlo Jakovljevic Farzad Jalilian Sudha Jayaraman Achala Upendra Jayatilleke Ravi Prakash Jha Yetunde O John-Akinola Jost B Jonas Kelly M Jones Nitin Joseph Farahnaz Joukar Jacek Jerzy Jozwiak Suresh Banayya Jungari Mikk Jürisson Ali Kabir Amaha Kahsay Leila R Kalankesh Rohollah Kalhor Teshome Abegaz Kamil Tanuj Kanchan Neeti Kapoor Manoochehr Karami Amir Kasaeian Hagazi Gebremedhin Kassaye Taras Kavetskyy Gbenga A Kayode Peter Njenga Keiyoro Abraham Getachew Kelbore Yousef Saleh Khader Morteza Abdullatif Khafaie Nauman Khalid Ibrahim A Khalil Rovshan Khalilov Maseer Khan Ejaz Ahmad Khan Junaid Khan Tripti Khanna Salman Khazaei Habibolah Khazaie Roba Khundkar Daniel N Kiirithio Young-Eun Kim Yun Jin Kim Daniel Kim Sezer Kisa Adnan Kisa Hamidreza Komaki Shivakumar K M Kondlahalli Ali Koolivand Vladimir Andreevich Korshunov Ai Koyanagi Moritz U G Kraemer Kewal Krishan Barthelemy Kuate Defo Burcu Kucuk Bicer Nuworza Kugbey Nithin Kumar Manasi Kumar Vivek Kumar Narinder Kumar Girikumar Kumaresh Faris Hasan Lami Van C Lansingh Savita Lasrado Arman Latifi Paolo Lauriola Carlo La Vecchia Janet L Leasher Shaun Wen Huey Lee Shanshan Li Xuefeng Liu Alan D Lopez Paulo A Lotufo Ronan A Lyons Daiane Borges Machado Mohammed Madadin Muhammed Magdy Abd El Razek Narayan Bahadur Mahotra Marek Majdan Azeem Majeed Venkatesh Maled Deborah Carvalho Malta Navid Manafi Amir Manafi Ana-Laura Manda Narayana Manjunatha Fariborz Mansour-Ghanaei Mohammad Ali Mansournia Joemer C Maravilla Amanda J Mason-Jones Seyedeh Zahra Masoumi Benjamin Ballard Massenburg Pallab K Maulik Man Mohan Mehndiratta Zeleke Aschalew Melketsedik Peter T N Memiah Walter Mendoza Ritesh G Menezes Melkamu Merid Mengesha Tuomo J Meretoja Atte Meretoja Hayimro Edemealem Merie Tomislav Mestrovic Bartosz Miazgowski Tomasz Miazgowski Ted R Miller G K Mini Andreea Mirica Erkin M Mirrakhimov Mehdi Mirzaei-Alavijeh Prasanna Mithra Babak Moazen Masoud Moghadaszadeh Efat Mohamadi Yousef Mohammad Aso Mohammad Darwesh Abdollah Mohammadian-Hafshejani Reza Mohammadpourhodki Shafiu Mohammed Jemal Abdu Mohammed Farnam Mohebi Mohammad A Mohseni Bandpei Mariam Molokhia Lorenzo Monasta Yoshan Moodley Masoud Moradi Ghobad Moradi Maziar Moradi-Lakeh Rahmatollah Moradzadeh Lidia Morawska Ilais Moreno Velásquez Shane Douglas Morrison Tilahun Belete Mossie Atalay Goshu Muluneh Kamarul Imran Musa Ghulam Mustafa Mehdi Naderi Ahamarshan Jayaraman Nagarajan Gurudatta Naik Mukhammad David Naimzada Farid Najafi Vinay Nangia Bruno Ramos Nascimento Morteza Naserbakht Vinod Nayak Javad Nazari Duduzile Edith Ndwandwe Ionut Negoi Josephine W Ngunjiri Trang Huyen Nguyen Cuong Tat Nguyen Diep Ngoc Nguyen Huong Lan Thi Nguyen Rajan Nikbakhsh Dina Nur Anggraini Ningrum Chukwudi A Nnaji Richard Ofori-Asenso Felix Akpojene Ogbo Onome Bright Oghenetega In-Hwan Oh Andrew T Olagunju Tinuke O Olagunju Ahmed Omar Bali Obinna E Onwujekwe Heather M Orpana Erika Ota Nikita Otstavnov Stanislav S Otstavnov Mahesh P A Jagadish Rao Padubidri Smita Pakhale Keyvan Pakshir Songhomitra Panda-Jonas Eun-Kee Park Sangram Kishor Patel Ashish Pathak Sanghamitra Pati Kebreab Paulos Amy E Peden Veincent Christian Filipino Pepito Jeevan Pereira Michael R Phillips Roman V Polibin Suzanne Polinder Farshad Pourmalek Akram Pourshams Hossein Poustchi Swayam Prakash Dimas Ria Angga Pribadi Parul Puri Zahiruddin Quazi Syed Navid Rabiee Mohammad Rabiee Amir Radfar Anwar Rafay Ata Rafiee Alireza Rafiei Fakher Rahim Siavash Rahimi Muhammad Aziz Rahman Ali Rajabpour-Sanati Fatemeh Rajati Ivo Rakovac Sowmya J Rao Vahid Rashedi Prateek Rastogi Priya Rathi Salman Rawaf Lal Rawal Reza Rawassizadeh Vishnu Renjith Serge Resnikoff Aziz Rezapour Ana Isabel Ribeiro Jennifer Rickard Carlos Miguel Rios González Leonardo Roever Luca Ronfani Gholamreza Roshandel Basema Saddik Hamid Safarpour Mahdi Safdarian S Mohammad Sajadi Payman Salamati Marwa R Rashad Salem Hosni Salem Inbal Salz Abdallah M Samy Juan Sanabria Lidia Sanchez Riera Milena M Santric Milicevic Abdur Razzaque Sarker Arash Sarveazad Brijesh Sathian Monika Sawhney Mehdi Sayyah David C Schwebel Soraya Seedat Subramanian Senthilkumaran Seyedmojtaba Seyedmousavi Feng Sha Faramarz Shaahmadi Saeed Shahabi Masood Ali Shaikh Mehran Shams-Beyranvand Aziz Sheikh Mika Shigematsu Jae Il Shin Rahman Shiri Soraya Siabani Inga Dora Sigfusdottir Jasvinder A Singh Pankaj Kumar Singh Dhirendra Narain Sinha Amin Soheili Joan B Soriano Muluken Bekele Sorrie Ireneous N Soyiri Mark A Stokes Mu'awiyyah Babale Sufiyan Bryan L Sykes Rafael Tabarés-Seisdedos Karen M Tabb Biruk Wogayehu Taddele Yonatal Mesfin Tefera Arash Tehrani-Banihashemi Gebretsadkan Hintsa Tekulu Ayenew Kassie Tesema Tesema Berhe Etsay Tesfay Rekha Thapar Mariya Vladimirovna Titova Kenean Getaneh Tlaye Hamid Reza Tohidinik Roman Topor-Madry Khanh Bao Tran Bach Xuan Tran Jaya Prasad Tripathy Alexander C Tsai Aristidis Tsatsakis Lorainne Tudor Car Irfan Ullah Saif Ullah Bhaskaran Unnikrishnan Era Upadhyay Olalekan A Uthman Pascual R Valdez Tommi Juhani Vasankari Yousef Veisani Narayanaswamy Venketasubramanian Francesco S Violante Vasily Vlassov Yasir Waheed Yuan-Pang Wang Taweewat Wiangkham Haileab Fekadu Wolde Dawit Habte Woldeyes Temesgen Gebeyehu Wondmeneh Adam Belay Wondmieneh Ai-Min Wu Grant M A Wyper Rajaram Yadav Ali Yadollahpour Yuichiro Yano Sanni Yaya Vahid Yazdi-Feyzabadi Pengpeng Ye Paul Yip Engida Yisma Naohiro Yonemoto Seok-Jun Yoon Yoosik Youm Mustafa Z Younis Zabihollah Yousefi Chuanhua Yu Yong Yu Telma Zahirian Moghadam Zoubida Zaidi Sojib Bin Zaman Mohammad Zamani Hamed Zandian Fatemeh Zarei Zhi-Jiang Zhang Yunquan Zhang Arash Ziapour Sanjay Zodpey Rakhi Dandona Samath Dhamminda Dharmaratne Simon I Hay Ali H Mokdad David M Pigott Robert C Reiner Theo Vos

Inj Prev 2020 Oct 24;26(Supp 1):i125-i153. Epub 2020 Aug 24.

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Background: While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria.

Methods: In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then estimating incidence for every cause of injury. Non-fatal disability for each cause is then calculated based on the probabilities of suffering from different types of bodily injury experienced.

Results: GBD 2017 produced morbidity and mortality estimates for 38 causes of injury. Estimates were produced in terms of incidence, prevalence, years lived with disability, cause-specific mortality, years of life lost and disability-adjusted life-years for a 28-year period for 22 age groups, 195 countries and both sexes.

Conclusions: GBD 2017 demonstrated a complex and sophisticated series of analytical steps using the largest known database of morbidity and mortality data on injuries. GBD 2017 results should be used to help inform injury prevention policy making and resource allocation. We also identify important avenues for improving injury burden estimation in the future.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/injuryprev-2019-043531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571362PMC
October 2020

Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017.

Authors:
Spencer L James Chris D Castle Zachary V Dingels Jack T Fox Erin B Hamilton Zichen Liu Nicholas L S Roberts Dillon O Sylte Nathaniel J Henry Kate E LeGrand Ahmed Abdelalim Amir Abdoli Ibrahim Abdollahpour Rizwan Suliankatchi Abdulkader Aidin Abedi Akine Eshete Abosetugn Abdelrahman I Abushouk Oladimeji M Adebayo Marcela Agudelo-Botero Tauseef Ahmad Rushdia Ahmed Muktar Beshir Ahmed Miloud Taki Eddine Aichour Fares Alahdab Genet Melak Alamene Fahad Mashhour Alanezi Animut Alebel Niguse Meles Alema Suliman A Alghnam Samar Al-Hajj Beriwan Abdulqadir Ali Saqib Ali Mahtab Alikhani Cyrus Alinia Vahid Alipour Syed Mohamed Aljunid Amir Almasi-Hashiani Nihad A Almasri Khalid Altirkawi Yasser Sami Abdeldayem Amer Saeed Amini Arianna Maever Loreche Amit Catalina Liliana Andrei Alireza Ansari-Moghaddam Carl Abelardo T Antonio Seth Christopher Yaw Appiah Jalal Arabloo Morteza Arab-Zozani Zohreh Arefi Olatunde Aremu Filippo Ariani Amit Arora Malke Asaad Babak Asghari Nefsu Awoke Beatriz Paulina Ayala Quintanilla Getinet Ayano Martin Amogre Ayanore Samad Azari Ghasem Azarian Alaa Badawi Ashish D Badiye Eleni Bagli Atif Amin Baig Mohan Bairwa Ahad Bakhtiari Arun Balachandran Maciej Banach Srikanta K Banerjee Palash Chandra Banik Amrit Banstola Suzanne Lyn Barker-Collo Till Winfried Bärnighausen Lope H Barrero Akbar Barzegar Mohsen Bayati Bayisa Abdissa Baye Neeraj Bedi Masoud Behzadifar Tariku Tesfaye Bekuma Habte Belete Corina Benjet Derrick A Bennett Isabela M Bensenor Kidanemaryam Berhe Pankaj Bhardwaj Anusha Ganapati Bhat Krittika Bhattacharyya Sadia Bibi Ali Bijani Muhammad Shahdaat Bin Sayeed Guilherme Borges Antonio Maria Borzì Soufiane Boufous Alexandra Brazinova Nikolay Ivanovich Briko Shyam S Budhathoki Josip Car Rosario Cárdenas Félix Carvalho João Mauricio Castaldelli-Maia Carlos A Castañeda-Orjuela Giulio Castelpietra Ferrán Catalá-López Ester Cerin Joht S Chandan Wagaye Fentahun Chanie Soosanna Kumary Chattu Vijay Kumar Chattu Irini Chatziralli Neha Chaudhary Daniel Youngwhan Cho Mohiuddin Ahsanul Kabir Chowdhury Dinh-Toi Chu Samantha M Colquhoun Maria-Magdalena Constantin Vera M Costa Giovanni Damiani Ahmad Daryani Claudio Alberto Dávila-Cervantes Feleke Mekonnen Demeke Asmamaw Bizuneh Demis Gebre Teklemariam Demoz Desalegn Getnet Demsie Afshin Derakhshani Kebede Deribe Rupak Desai Mostafa Dianati Nasab Diana Dias da Silva Zahra Sadat Dibaji Forooshani Kerrie E Doyle Tim Robert Driscoll Eleonora Dubljanin Bereket Duko Adema Arielle Wilder Eagan Aziz Eftekhari Elham Ehsani-Chimeh Maysaa El Sayed Zaki Demelash Abewa Elemineh Shaimaa I El-Jaafary Ziad El-Khatib Christian Lycke Ellingsen Mohammad Hassan Emamian Daniel Adane Endalew Sharareh Eskandarieh Pawan Sirwan Faris Andre Faro Farshad Farzadfar Yousef Fatahi Wubalem Fekadu Tomas Y Ferede Seyed-Mohammad Fereshtehnejad Eduarda Fernandes Pietro Ferrara Garumma Tolu Feyissa Irina Filip Florian Fischer Morenike Oluwatoyin Folayan Masoud Foroutan Joel Msafiri Francis Richard Charles Franklin Takeshi Fukumoto Biniyam Sahiledengle Geberemariyam Abadi Kahsu Gebre Ketema Bizuwork Gebremedhin Gebreamlak Gebremedhn Gebremeskel Berhe Gebremichael Getnet Azeze Gedefaw Birhanu Geta Mansour Ghafourifard Farhad Ghamari Ahmad Ghashghaee Asadollah Gholamian Tiffany K Gill Alessandra C Goulart Ayman Grada Michal Grivna Mohammed Ibrahim Mohialdeen Gubari Rafael Alves Guimarães Yuming Guo Gaurav Gupta Juanita A Haagsma Nima Hafezi-Nejad Hassan Haghparast Bidgoli Brian James Hall Randah R Hamadeh Samer Hamidi Josep Maria Haro Md Mehedi Hasan Amir Hasanzadeh Soheil Hassanipour Hadi Hassankhani Hamid Yimam Hassen Rasmus Havmoeller Khezar Hayat Delia Hendrie Fatemeh Heydarpour Martha Híjar Hung Chak Ho Chi Linh Hoang Michael K Hole Ramesh Holla Naznin Hossain Mehdi Hosseinzadeh Sorin Hostiuc Guoqing Hu Segun Emmanuel Ibitoye Olayinka Stephen Ilesanmi Irena Ilic Milena D Ilic Leeberk Raja Inbaraj Endang Indriasih Seyed Sina Naghibi Irvani Sheikh Mohammed Shariful Islam M Mofizul Islam Rebecca Q Ivers Kathryn H Jacobsen Mohammad Ali Jahani Nader Jahanmehr Mihajlo Jakovljevic Farzad Jalilian Sudha Jayaraman Achala Upendra Jayatilleke Ravi Prakash Jha Yetunde O John-Akinola Jost B Jonas Nitin Joseph Farahnaz Joukar Jacek Jerzy Jozwiak Suresh Banayya Jungari Mikk Jürisson Ali Kabir Rajendra Kadel Amaha Kahsay Leila R Kalankesh Rohollah Kalhor Teshome Abegaz Kamil Tanuj Kanchan Neeti Kapoor Manoochehr Karami Amir Kasaeian Hagazi Gebremedhin Kassaye Taras Kavetskyy Hafte Kahsay Kebede Peter Njenga Keiyoro Abraham Getachew Kelbore Bayew Kelkay Yousef Saleh Khader Morteza Abdullatif Khafaie Nauman Khalid Ibrahim A Khalil Rovshan Khalilov Mohammad Khammarnia Ejaz Ahmad Khan Maseer Khan Tripti Khanna Habibolah Khazaie Fatemeh Khosravi Shadmani Roba Khundkar Daniel N Kiirithio Young-Eun Kim Daniel Kim Yun Jin Kim Adnan Kisa Sezer Kisa Hamidreza Komaki Shivakumar K M Kondlahalli Vladimir Andreevich Korshunov Ai Koyanagi Moritz U G Kraemer Kewal Krishan Burcu Kucuk Bicer Nuworza Kugbey Vivek Kumar Nithin Kumar G Anil Kumar Manasi Kumar Girikumar Kumaresh Om P Kurmi Oluwatosin Kuti Carlo La Vecchia Faris Hasan Lami Prabhat Lamichhane Justin J Lang Van C Lansingh Dennis Odai Laryea Savita Lasrado Arman Latifi Paolo Lauriola Janet L Leasher Shaun Wen Huey Lee Tsegaye Lolaso Lenjebo Miriam Levi Shanshan Li Shai Linn Xuefeng Liu Alan D Lopez Paulo A Lotufo Raimundas Lunevicius Ronan A Lyons Mohammed Madadin Muhammed Magdy Abd El Razek Narayan Bahadur Mahotra Marek Majdan Azeem Majeed Jeadran N Malagon-Rojas Venkatesh Maled Reza Malekzadeh Deborah Carvalho Malta Navid Manafi Amir Manafi Ana-Laura Manda Narayana Manjunatha Fariborz Mansour-Ghanaei Borhan Mansouri Mohammad Ali Mansournia Joemer C Maravilla Lyn M March Amanda J Mason-Jones Seyedeh Zahra Masoumi Benjamin Ballard Massenburg Pallab K Maulik Gebrekiros Gebremichael Meles Addisu Melese Zeleke Aschalew Melketsedik Peter T N Memiah Walter Mendoza Ritesh G Menezes Meresa Berwo Mengesha Melkamu Merid Mengesha Tuomo J Meretoja Atte Meretoja Hayimro Edemealem Merie Tomislav Mestrovic Bartosz Miazgowski Tomasz Miazgowski Ted R Miller G K Mini Andreea Mirica Erkin M Mirrakhimov Mehdi Mirzaei-Alavijeh Prasanna Mithra Babak Moazen Masoud Moghadaszadeh Efat Mohamadi Yousef Mohammad Karzan Abdulmuhsin Mohammad Aso Mohammad Darwesh Naser Mohammad Gholi Mezerji Abdollah Mohammadian-Hafshejani Milad Mohammadoo-Khorasani Reza Mohammadpourhodki Shafiu Mohammed Jemal Abdu Mohammed Farnam Mohebi Mariam Molokhia Lorenzo Monasta Yoshan Moodley Mahmood Moosazadeh Masoud Moradi Ghobad Moradi Maziar Moradi-Lakeh Farhad Moradpour Lidia Morawska Ilais Moreno Velásquez Naho Morisaki Shane Douglas Morrison Tilahun Belete Mossie Atalay Goshu Muluneh Srinivas Murthy Kamarul Imran Musa Ghulam Mustafa Ashraf F Nabhan Ahamarshan Jayaraman Nagarajan Gurudatta Naik Mukhammad David Naimzada Farid Najafi Vinay Nangia Bruno Ramos Nascimento Morteza Naserbakht Vinod Nayak Duduzile Edith Ndwandwe Ionut Negoi Josephine W Ngunjiri Cuong Tat Nguyen Huong Lan Thi Nguyen Rajan Nikbakhsh Dina Nur Anggraini Ningrum Chukwudi A Nnaji Peter S Nyasulu Felix Akpojene Ogbo Onome Bright Oghenetega In-Hwan Oh Emmanuel Wandera Okunga Andrew T Olagunju Tinuke O Olagunju Ahmed Omar Bali Obinna E Onwujekwe Kwaku Oppong Asante Heather M Orpana Erika Ota Nikita Otstavnov Stanislav S Otstavnov Mahesh P A Jagadish Rao Padubidri Smita Pakhale Keyvan Pakshir Songhomitra Panda-Jonas Eun-Kee Park Sangram Kishor Patel Ashish Pathak Sanghamitra Pati George C Patton Kebreab Paulos Amy E Peden Veincent Christian Filipino Pepito Jeevan Pereira Hai Quang Pham Michael R Phillips Marina Pinheiro Roman V Polibin Suzanne Polinder Hossein Poustchi Swayam Prakash Dimas Ria Angga Pribadi Parul Puri Zahiruddin Quazi Syed Mohammad Rabiee Navid Rabiee Amir Radfar Anwar Rafay Ata Rafiee Alireza Rafiei Fakher Rahim Siavash Rahimi Vafa Rahimi-Movaghar Muhammad Aziz Rahman Ali Rajabpour-Sanati Fatemeh Rajati Ivo Rakovac Kavitha Ranganathan Sowmya J Rao Vahid Rashedi Prateek Rastogi Priya Rathi Salman Rawaf Lal Rawal Reza Rawassizadeh Vishnu Renjith Andre M N Renzaho Serge Resnikoff Aziz Rezapour Ana Isabel Ribeiro Jennifer Rickard Carlos Miguel Rios González Luca Ronfani Gholamreza Roshandel Anas M Saad Yogesh Damodar Sabde Siamak Sabour Basema Saddik Saeed Safari Roya Safari-Faramani Hamid Safarpour Mahdi Safdarian S Mohammad Sajadi Payman Salamati Farkhonde Salehi Saleh Salehi Zahabi Marwa R Rashad Salem Hosni Salem Omar Salman Inbal Salz Abdallah M Samy Juan Sanabria Lidia Sanchez Riera Milena M Santric Milicevic Abdur Razzaque Sarker Arash Sarveazad Brijesh Sathian Monika Sawhney Susan M Sawyer Sonia Saxena Mehdi Sayyah David C Schwebel Soraya Seedat Subramanian Senthilkumaran Sadaf G Sepanlou Seyedmojtaba Seyedmousavi Feng Sha Faramarz Shaahmadi Saeed Shahabi Masood Ali Shaikh Mehran Shams-Beyranvand Morteza Shamsizadeh Mahdi Sharif-Alhoseini Hamid Sharifi Aziz Sheikh Mika Shigematsu Jae Il Shin Rahman Shiri Soraya Siabani Inga Dora Sigfusdottir Pankaj Kumar Singh Jasvinder A Singh Dhirendra Narain Sinha Catalin-Gabriel Smarandache Emma U R Smith Amin Soheili Bija Soleymani Ali Reza Soltanian Joan B Soriano Muluken Bekele Sorrie Ireneous N Soyiri Dan J Stein Mark A Stokes Mu'awiyyah Babale Sufiyan Hafiz Ansar Rasul Suleria Bryan L Sykes Rafael Tabarés-Seisdedos Karen M Tabb Biruk Wogayehu Taddele Degena Bahrey Tadesse Animut Tagele Tamiru Ingan Ukur Tarigan Yonatal Mesfin Tefera Arash Tehrani-Banihashemi Merhawi Gebremedhin Tekle Gebretsadkan Hintsa Tekulu Ayenew Kassie Tesema Berhe Etsay Tesfay Rekha Thapar Asres Bedaso Tilahune Kenean Getaneh Tlaye Hamid Reza Tohidinik Roman Topor-Madry Bach Xuan Tran Khanh Bao Tran Jaya Prasad Tripathy Alexander C Tsai Lorainne Tudor Car Saif Ullah Irfan Ullah Maida Umar Bhaskaran Unnikrishnan Era Upadhyay Olalekan A Uthman Pascual R Valdez Tommi Juhani Vasankari Narayanaswamy Venketasubramanian Francesco S Violante Vasily Vlassov Yasir Waheed Girmay Teklay Weldesamuel Andrea Werdecker Taweewat Wiangkham Haileab Fekadu Wolde Dawit Habte Woldeyes Dawit Zewdu Wondafrash Temesgen Gebeyehu Wondmeneh Adam Belay Wondmieneh Ai-Min Wu Rajaram Yadav Ali Yadollahpour Yuichiro Yano Sanni Yaya Vahid Yazdi-Feyzabadi Paul Yip Engida Yisma Naohiro Yonemoto Seok-Jun Yoon Yoosik Youm Mustafa Z Younis Zabihollah Yousefi Yong Yu Chuanhua Yu Hasan Yusefzadeh Telma Zahirian Moghadam Zoubida Zaidi Sojib Bin Zaman Mohammad Zamani Maryam Zamanian Hamed Zandian Ahmad Zarei Fatemeh Zare Zhi-Jiang Zhang Yunquan Zhang Sanjay Zodpey Lalit Dandona Rakhi Dandona Louisa Degenhardt Samath Dhamminda Dharmaratne Simon I Hay Ali H Mokdad Robert C Reiner Benn Sartorius Theo Vos

Inj Prev 2020 Oct 24;26(Supp 1):i96-i114. Epub 2020 Apr 24.

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Background: Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries.

Methods: We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs).

Findings: In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505).

Interpretation: Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/injuryprev-2019-043494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571366PMC
October 2020

and are Associated with Type 2 Diabetes Mellitus in Iranian Patients.

Diabetes Metab Syndr Obes 2020 24;13:897-906. Epub 2020 Mar 24.

Department of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran.

Background: Type 2 diabetes mellitus (T2DM) is a serious public health issue with significantly increasing rates across the world. The genome-wide association studies (GWAS) have previously manifested involved genes that remarkably enhance the risk of T2DM. In this study, the association of common variants with T2DM risk has been identified among Iranian population from Tehran province of Iran.

Methods: Here, the association of refSNPs with T2DM risk was examined on peripheral blood samples of 268 individuals including control group and patients with T2DM using the tetra amplification refractory mutation system (ARMS) methods and direct genomic DNA sequencing.

Results: Our study demonstrated that rs13266634 (T/C), rs10946398 (A/C), rs7903146 (C/T), rs2237892 (T/C), and rs1470579 (A/C) polymorphisms are significantly associated with type 2 diabetes, but no significant association was identified for FTO rs8050136 and MTNR1B rs10830963 polymorphisms.

Conclusion: The prediction of refSNPs is remarkably needed for pharmacogenetics and pharmacogenomic approaches, in which the information would be useful for clinicians to optimize therapeutic strategies and adverse drug reactions in patients with T2DM.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2147/DMSO.S225968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102914PMC
March 2020

Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017.

Authors:
Spencer L James Lydia R Lucchesi Catherine Bisignano Chris D Castle Zachary V Dingels Jack T Fox Erin B Hamilton Zichen Liu Darrah McCracken Molly R Nixon Dillon O Sylte Nicholas L S Roberts Oladimeji M Adebayo Teamur Aghamolaei Suliman A Alghnam Syed Mohamed Aljunid Amir Almasi-Hashiani Alaa Badawi Masoud Behzadifar Meysam Behzadifar Eyasu Tamru Bekru Derrick A Bennett Jens Robert Chapman Kebede Deribe Bereket Duko Adema Yousef Fatahi Belayneh K Gelaw Eskezyiaw Agedew Getahun Delia Hendrie Andualem Henok Hagos de Hidru Mehdi Hosseinzadeh Guoqing Hu Mohammad Ali Jahani Mihajlo Jakovljevic Farzad Jalilian Nitin Joseph Manoochehr Karami Abraham Getachew Kelbore Md Nuruzzaman Khan Yun Jin Kim Parvaiz A Koul Carlo La Vecchia Shai Linn Reza Majdzadeh Man Mohan Mehndiratta Peter T N Memiah Melkamu Merid Mengesha Hayimro Edemealem Merie Ted R Miller Mehdi Mirzaei-Alavijeh Aso Mohammad Darwesh Naser Mohammad Gholi Mezerji Roghayeh Mohammadibakhsh Yoshan Moodley Maziar Moradi-Lakeh Kamarul Imran Musa Bruno Ramos Nascimento Rajan Nikbakhsh Peter S Nyasulu Ahmed Omar Bali Obinna E Onwujekwe Sanghamitra Pati Reza Pourmirza Kalhori Farkhonde Salehi Saeed Shahabi Seifadin Ahmed Shallo Morteza Shamsizadeh Zeinab Sharafi Sharvari Rahul Shukla Mohammad Reza Sobhiyeh Joan B Soriano Bryan L Sykes Rafael Tabarés-Seisdedos Degena Bahray Bahrey Tadesse Yonatal Mesfin Tefera Arash Tehrani-Banihashemi Boikhutso Tlou Roman Topor-Madry Taweewat Wiangkham Mehdi Yaseri Sanni Yaya Muluken Azage Yenesew Mustafa Z Younis Arash Ziapour Sanjay Zodpey David M Pigott Robert C Reiner Simon I Hay Alan D Lopez Ali H Mokdad

Inj Prev 2020 Oct 8;26(Supp 1):i46-i56. Epub 2020 Jan 8.

Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.

Background: The global burden of road injuries is known to follow complex geographical, temporal and demographic patterns. While health loss from road injuries is a major topic of global importance, there has been no recent comprehensive assessment that includes estimates for every age group, sex and country over recent years.

Methods: We used results from the Global Burden of Disease (GBD) 2017 study to report incidence, prevalence, years lived with disability, deaths, years of life lost and disability-adjusted life years for all locations in the GBD 2017 hierarchy from 1990 to 2017 for road injuries. Second, we measured mortality-to-incidence ratios by location. Third, we assessed the distribution of the natures of injury (eg, traumatic brain injury) that result from each road injury.

Results: Globally, 1 243 068 (95% uncertainty interval 1 191 889 to 1 276 940) people died from road injuries in 2017 out of 54 192 330 (47 381 583 to 61 645 891) new cases of road injuries. Age-standardised incidence rates of road injuries increased between 1990 and 2017, while mortality rates decreased. Regionally, age-standardised mortality rates decreased in all but two regions, South Asia and Southern Latin America, where rates did not change significantly. Nine of 21 GBD regions experienced significant increases in age-standardised incidence rates, while 10 experienced significant decreases and two experienced no significant change.

Conclusions: While road injury mortality has improved in recent decades, there are worsening rates of incidence and significant geographical heterogeneity. These findings indicate that more research is needed to better understand how road injuries can be prevented.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/injuryprev-2019-043302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571357PMC
October 2020

The Requirements of Strategic Purchasing of Health Services for Cancer Patients: A Qualitative Study in Iran.

Health Care Manag (Frederick) 2020 Jan/Mar;39(1):35-45

Author Affiliations: Medical & Health Services Administration (Ms Yaghoubian) and Hospital Administration Research Center (Dr Mahmoudi), Sari Branch, Islamic Azad University, Sari; and Social Determinants of Health Research Center, Health Research Institute, School of Medicine, Babol University of Medical Sciences, Babol (Dr Jahani), Iran.

The strategic purchasing creates dynamics and providers' competitiveness among the internal market of governmental sector with ensuring appropriate payments and promoting quantity-quality of service delivery that lead to improve the health system efficiency. This study aimed to determine the requirements for the strategic purchasing of health services for cancer patients in Iran. As a qualitative research with a framework analysis, this study was conducted in Iran from July 2018 to February 2019. The participants were included some administrating managers, experts, and specialists of insurance selected purposefully by snowball sampling method. The framework analysis of the study included 5 steps. Data were saturated after 21 semistructured interviews. The main findings included 3 main themes (supply management, insurance trusteeship, and financial performance) and 14 subthemes (strategic purchasing infrastructures, practical guidelines, trusteeship structure, service package, service quality, service quantity, role of other organizations and groups, training, establishment of an insurance thought, strategic management, communication, price, efficiency and effectiveness, and resource provision). The strategic purchasing model of health services increases the power of service purchasers and payment based on defined priorities, resulting in providers' coordinating for care provision, enhancement of financial performance and cancer patients' better access to health services, improvement of life quality, and financial protection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/HCM.0000000000000286DOI Listing
September 2020

A 25-year trend in gastrointestinal cancers in northern Iran (1991-2016).

Caspian J Intern Med 2019 ;10(4):396-401

Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Background: Identifying the incidence of cancer helps in planning and prioritizing resources for its screening, prevention, treatment and diagnosis. This study aimed at investigating a 25-year trend in gastrointestinal cancer in northern Iran during 1991-2016.

Methods: This research was a trend analysis. The study population was one thousand five hundred and thirty-five cancer patients referring to Shahid Rajai Hospital in Babolsar, northern Iran, as the only center for radiotherapy in the North of Iran, during 1991-2016. SPSS version 22 was used for entering data and t-test, ᵡ2 and ANOVA were used for analyzing data in the significant level of ≤0.05.

Results: The highest incidence of stomach cancer was 111 (35%) in 2011 and the lowest incidence was 44 (16.3%) in 1996, The highest frequency of esophageal cancer was reported 137(56.1%) cases in 1991 and the lowest frequency was 78 (26.3%) cases in 2016, while the highest incidence of colorectal cancer was 109 (36.7%) cases in 2016 and its lowest frequency was 32 (16.3%) in 1996. There was also a significant difference in the frequency of gastrointestinal cancers in different studied years (p <0.001).

Conclusion: The trends in the incidence of stomach and colorectal cancers in northern Iran were increasing while esophageal cancer was decreasing.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.22088/cjim.10.4.396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856909PMC
January 2019

An A10398G mitochondrial DNA alteration is related to increased risk of breast cancer, and associates with Her2 positive receptor.

Mitochondrial DNA A DNA Mapp Seq Anal 2020 01 4;31(1):11-16. Epub 2019 Dec 4.

Department of Medical Genetic, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran.

Breast cancer is the most common malignancy and the second leading cause of cancer deaths among women worldwide after lung cancer. Mitochondria play a central role in the regulation of cellular function, metabolism, and cell death in cancer cells. We aim to examine the mitochondrial polymorphisms of complex I in association with breast cancer in an Iranian cohort.This experimental study includes 53 patients with breast cancer and 35 healthy control patients. In addition, tumor-adjacent normal breast tissue was obtained from each patient. The DNA of the tissue cells was extracted and analyzed for complex I mutations using a PCR sequencing method. Our results show 94 mtDNA complex I variants in tumor tissues. A10398G was the most prevalent polymorphism and strongly correlated with Her2 receptor in tumor tissue samples. Mitochondrial DNA (mtDNA) mutations have been widely linked to the etiology of numerous disorders. The mtDNA mutations screening on A10398G along with other mutations might provide insight on the role of mitochondrial mutations in breast cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/24701394.2019.1695788DOI Listing
January 2020

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

Authors:
Christina Fitzmaurice Degu Abate Naghmeh Abbasi Hedayat Abbastabar Foad Abd-Allah Omar Abdel-Rahman Ahmed Abdelalim Amir Abdoli Ibrahim Abdollahpour Abdishakur S M Abdulle Nebiyu Dereje Abebe Haftom Niguse Abraha Laith Jamal Abu-Raddad Ahmed Abualhasan Isaac Akinkunmi Adedeji Shailesh M Advani Mohsen Afarideh Mahdi Afshari Mohammad Aghaali Dominic Agius Sutapa Agrawal Ayat Ahmadi Elham Ahmadian Ehsan Ahmadpour Muktar Beshir Ahmed Mohammad Esmaeil Akbari Tomi Akinyemiju Ziyad Al-Aly Assim M AlAbdulKader Fares Alahdab Tahiya Alam Genet Melak Alamene Birhan Tamene T Alemnew Kefyalew Addis Alene Cyrus Alinia Vahid Alipour Syed Mohamed Aljunid Fatemeh Allah Bakeshei Majid Abdulrahman Hamad Almadi Amir Almasi-Hashiani Ubai Alsharif Shirina Alsowaidi Nelson Alvis-Guzman Erfan Amini Saeed Amini Yaw Ampem Amoako Zohreh Anbari Nahla Hamed Anber Catalina Liliana Andrei Mina Anjomshoa Fereshteh Ansari Ansariadi Ansariadi Seth Christopher Yaw Appiah Morteza Arab-Zozani Jalal Arabloo Zohreh Arefi Olatunde Aremu Habtamu Abera Areri Al Artaman Hamid Asayesh Ephrem Tsegay Asfaw Alebachew Fasil Ashagre Reza Assadi Bahar Ataeinia Hagos Tasew Atalay Zerihun Ataro Suleman Atique Marcel Ausloos Leticia Avila-Burgos Euripide F G A Avokpaho Ashish Awasthi Nefsu Awoke Beatriz Paulina Ayala Quintanilla Martin Amogre Ayanore Henok Tadesse Ayele Ebrahim Babaee Umar Bacha Alaa Badawi Mojtaba Bagherzadeh Eleni Bagli Senthilkumar Balakrishnan Abbas Balouchi Till Winfried Bärnighausen Robert J Battista Masoud Behzadifar Meysam Behzadifar Bayu Begashaw Bekele Yared Belete Belay Yaschilal Muche Belayneh Kathleen Kim Sachiko Berfield Adugnaw Berhane Eduardo Bernabe Mircea Beuran Nickhill Bhakta Krittika Bhattacharyya Belete Biadgo Ali Bijani Muhammad Shahdaat Bin Sayeed Charles Birungi Catherine Bisignano Helen Bitew Tone Bjørge Archie Bleyer Kassawmar Angaw Bogale Hunduma Amensisa Bojia Antonio M Borzì Cristina Bosetti Ibrahim R Bou-Orm Hermann Brenner Jerry D Brewer Andrey Nikolaevich Briko Nikolay Ivanovich Briko Maria Teresa Bustamante-Teixeira Zahid A Butt Giulia Carreras Juan J Carrero Félix Carvalho Clara Castro Franz Castro Ferrán Catalá-López Ester Cerin Yazan Chaiah Wagaye Fentahun Chanie Vijay Kumar Chattu Pankaj Chaturvedi Neelima Singh Chauhan Mohammad Chehrazi Peggy Pei-Chia Chiang Tesfaye Yitna Chichiabellu Onyema Greg Chido-Amajuoyi Odgerel Chimed-Ochir Jee-Young J Choi Devasahayam J Christopher Dinh-Toi Chu Maria-Magdalena Constantin Vera M Costa Emanuele Crocetti Christopher Stephen Crowe Maria Paula Curado Saad M A Dahlawi Giovanni Damiani Amira Hamed Darwish Ahmad Daryani José das Neves Feleke Mekonnen Demeke Asmamaw Bizuneh Demis Birhanu Wondimeneh Demissie Gebre Teklemariam Demoz Edgar Denova-Gutiérrez Afshin Derakhshani Kalkidan Solomon Deribe Rupak Desai Beruk Berhanu Desalegn Melaku Desta Subhojit Dey Samath Dhamminda Dharmaratne Meghnath Dhimal Daniel Diaz Mesfin Tadese Tadese Dinberu Shirin Djalalinia David Teye Doku Thomas M Drake Manisha Dubey Eleonora Dubljanin Eyasu Ejeta Duken Hedyeh Ebrahimi Andem Effiong Aziz Eftekhari Iman El Sayed Maysaa El Sayed Zaki Shaimaa I El-Jaafary Ziad El-Khatib Demelash Abewa Elemineh Hajer Elkout Richard G Ellenbogen Aisha Elsharkawy Mohammad Hassan Emamian Daniel Adane Endalew Aman Yesuf Endries Babak Eshrati Ibtihal Fadhil Vahid Fallah Omrani Mahbobeh Faramarzi Mahdieh Abbasalizad Farhangi Andrea Farioli Farshad Farzadfar Netsanet Fentahun Eduarda Fernandes Garumma Tolu Feyissa Irina Filip Florian Fischer James L Fisher Lisa M Force Masoud Foroutan Marisa Freitas Takeshi Fukumoto Neal D Futran Silvano Gallus Fortune Gbetoho Gankpe Reta Tsegaye Gayesa Tsegaye Tewelde Gebrehiwot Gebreamlak Gebremedhn Gebremeskel Getnet Azeze Gedefaw Belayneh K Gelaw Birhanu Geta Sefonias Getachew Kebede Embaye Gezae Mansour Ghafourifard Alireza Ghajar Ahmad Ghashghaee Asadollah Gholamian Paramjit Singh Gill Themba T G Ginindza Alem Girmay Muluken Gizaw Ricardo Santiago Gomez Sameer Vali Gopalani Giuseppe Gorini Bárbara Niegia Garcia Goulart Ayman Grada Maximiliano Ribeiro Guerra Andre Luiz Sena Guimaraes Prakash C Gupta Rahul Gupta Kishor Hadkhale Arvin Haj-Mirzaian Arya Haj-Mirzaian Randah R Hamadeh Samer Hamidi Lolemo Kelbiso Hanfore Josep Maria Haro Milad Hasankhani Amir Hasanzadeh Hamid Yimam Hassen Roderick J Hay Simon I Hay Andualem Henok Nathaniel J Henry Claudiu Herteliu Hagos D Hidru Chi Linh Hoang Michael K Hole Praveen Hoogar Nobuyuki Horita H Dean Hosgood Mostafa Hosseini Mehdi Hosseinzadeh Mihaela Hostiuc Sorin Hostiuc Mowafa Househ Mohammedaman Mama Hussen Bogdan Ileanu Milena D Ilic Kaire Innos Seyed Sina Naghibi Irvani Kufre Robert Iseh Sheikh Mohammed Shariful Islam Farhad Islami Nader Jafari Balalami Morteza Jafarinia Leila Jahangiry Mohammad Ali Jahani Nader Jahanmehr Mihajlo Jakovljevic Spencer L James Mehdi Javanbakht Sudha Jayaraman Sun Ha Jee Ensiyeh Jenabi Ravi Prakash Jha Jost B Jonas Jitendra Jonnagaddala Tamas Joo Suresh Banayya Jungari Mikk Jürisson Ali Kabir Farin Kamangar André Karch Narges Karimi Ansar Karimian Amir Kasaeian Gebremicheal Gebreslassie Kasahun Belete Kassa Tesfaye Dessale Kassa Mesfin Wudu Kassaw Anil Kaul Peter Njenga Keiyoro Abraham Getachew Kelbore Amene Abebe Kerbo Yousef Saleh Khader Maryam Khalilarjmandi Ejaz Ahmad Khan Gulfaraz Khan Young-Ho Khang Khaled Khatab Amir Khater Maryam Khayamzadeh Maryam Khazaee-Pool Salman Khazaei Abdullah T Khoja Mohammad Hossein Khosravi Jagdish Khubchandani Neda Kianipour Daniel Kim Yun Jin Kim Adnan Kisa Sezer Kisa Katarzyna Kissimova-Skarbek Hamidreza Komaki Ai Koyanagi Kristopher J Krohn Burcu Kucuk Bicer Nuworza Kugbey Vivek Kumar Desmond Kuupiel Carlo La Vecchia Deepesh P Lad Eyasu Alem Lake Ayenew Molla Lakew Dharmesh Kumar Lal Faris Hasan Lami Qing Lan Savita Lasrado Paolo Lauriola Jeffrey V Lazarus James Leigh Cheru Tesema Leshargie Yu Liao Miteku Andualem Limenih Stefan Listl Alan D Lopez Platon D Lopukhov Raimundas Lunevicius Mohammed Madadin Sameh Magdeldin Hassan Magdy Abd El Razek Azeem Majeed Afshin Maleki Reza Malekzadeh Ali Manafi Navid Manafi Wondimu Ayele Manamo Morteza Mansourian Mohammad Ali Mansournia Lorenzo Giovanni Mantovani Saman Maroufizadeh Santi Martini S Martini Tivani Phosa Mashamba-Thompson Benjamin Ballard Massenburg Motswadi Titus Maswabi Manu Raj Mathur Colm McAlinden Martin McKee Hailemariam Abiy Alemu Meheretu Ravi Mehrotra Varshil Mehta Toni Meier Yohannes A Melaku Gebrekiros Gebremichael Meles Hagazi Gebre Meles Addisu Melese Mulugeta Melku Peter T N Memiah Walter Mendoza Ritesh G Menezes Shahin Merat Tuomo J Meretoja Tomislav Mestrovic Bartosz Miazgowski Tomasz Miazgowski Kebadnew Mulatu M Mihretie Ted R Miller Edward J Mills Seyed Mostafa Mir Hamed Mirzaei Hamid Reza Mirzaei Rashmi Mishra Babak Moazen Dara K Mohammad Karzan Abdulmuhsin Mohammad Yousef Mohammad Aso Mohammad Darwesh Abolfazl Mohammadbeigi Hiwa Mohammadi Moslem Mohammadi Mahdi Mohammadian Abdollah Mohammadian-Hafshejani Milad Mohammadoo-Khorasani Reza Mohammadpourhodki Ammas Siraj Mohammed Jemal Abdu Mohammed Shafiu Mohammed Farnam Mohebi Ali H Mokdad Lorenzo Monasta Yoshan Moodley Mahmood Moosazadeh Maryam Moossavi Ghobad Moradi Mohammad Moradi-Joo Maziar Moradi-Lakeh Farhad Moradpour Lidia Morawska Joana Morgado-da-Costa Naho Morisaki Shane Douglas Morrison Abbas Mosapour Seyyed Meysam Mousavi Achenef Asmamaw Muche Oumer Sada S Muhammed Jonah Musa Ashraf F Nabhan Mehdi Naderi Ahamarshan Jayaraman Nagarajan Gabriele Nagel Azin Nahvijou Gurudatta Naik Farid Najafi Luigi Naldi Hae Sung Nam Naser Nasiri Javad Nazari Ionut Negoi Subas Neupane Polly A Newcomb Haruna Asura Nggada Josephine W Ngunjiri Cuong Tat Nguyen Leila Nikniaz Dina Nur Anggraini Ningrum Yirga Legesse Nirayo Molly R Nixon Chukwudi A Nnaji Marzieh Nojomi Shirin Nosratnejad Malihe Nourollahpour Shiadeh Mohammed Suleiman Obsa Richard Ofori-Asenso Felix Akpojene Ogbo In-Hwan Oh Andrew T Olagunju Tinuke O Olagunju Mojisola Morenike Oluwasanu Abidemi E Omonisi Obinna E Onwujekwe Anu Mary Oommen Eyal Oren Doris D V Ortega-Altamirano Erika Ota Stanislav S Otstavnov Mayowa Ojo Owolabi Mahesh P A Jagadish Rao Padubidri Smita Pakhale Amir H Pakpour Adrian Pana Eun-Kee Park Hadi Parsian Tahereh Pashaei Shanti Patel Snehal T Patil Alyssa Pennini David M Pereira Cristiano Piccinelli Julian David Pillay Majid Pirestani Farhad Pishgar Maarten J Postma Hadi Pourjafar Farshad Pourmalek Akram Pourshams Swayam Prakash Narayan Prasad Mostafa Qorbani Mohammad Rabiee Navid Rabiee Amir Radfar Alireza Rafiei Fakher Rahim Mahdi Rahimi Muhammad Aziz Rahman Fatemeh Rajati Saleem M Rana Samira Raoofi Goura Kishor Rath David Laith Rawaf Salman Rawaf Robert C Reiner Andre M N Renzaho Nima Rezaei Aziz Rezapour Ana Isabel Ribeiro Daniela Ribeiro Luca Ronfani Elias Merdassa Roro Gholamreza Roshandel Ali Rostami Ragy Safwat Saad Parisa Sabbagh Siamak Sabour Basema Saddik Saeid Safiri Amirhossein Sahebkar Mohammad Reza Salahshoor Farkhonde Salehi Hosni Salem Marwa Rashad Salem Hamideh Salimzadeh Joshua A Salomon Abdallah M Samy Juan Sanabria Milena M Santric Milicevic Benn Sartorius Arash Sarveazad Brijesh Sathian Maheswar Satpathy Miloje Savic Monika Sawhney Mehdi Sayyah Ione J C Schneider Ben Schöttker Mario Sekerija Sadaf G Sepanlou Masood Sepehrimanesh Seyedmojtaba Seyedmousavi Faramarz Shaahmadi Hosein Shabaninejad Mohammad Shahbaz Masood Ali Shaikh Amir Shamshirian Morteza Shamsizadeh Heidar Sharafi Zeinab Sharafi Mehdi Sharif Ali Sharifi Hamid Sharifi Rajesh Sharma Aziz Sheikh Reza Shirkoohi Sharvari Rahul Shukla Si Si Soraya Siabani Diego Augusto Santos Silva Dayane Gabriele Alves Silveira Ambrish Singh Jasvinder A Singh Solomon Sisay Freddy Sitas Eugène Sobngwi Moslem Soofi Joan B Soriano Vasiliki Stathopoulou Mu'awiyyah Babale Sufiyan Rafael Tabarés-Seisdedos Takahiro Tabuchi Ken Takahashi Omid Reza Tamtaji Mohammed Rasoul Tarawneh Segen Gebremeskel Tassew Parvaneh Taymoori Arash Tehrani-Banihashemi Mohamad-Hani Temsah Omar Temsah Berhe Etsay Tesfay Fisaha Haile Tesfay Manaye Yihune Teshale Gizachew Assefa Tessema Subash Thapa Kenean Getaneh Tlaye Roman Topor-Madry Marcos Roberto Tovani-Palone Eugenio Traini Bach Xuan Tran Khanh Bao Tran Afewerki Gebremeskel Tsadik Irfan Ullah Olalekan A Uthman Marco Vacante Maryam Vaezi Patricia Varona Pérez Yousef Veisani Simone Vidale Francesco S Violante Vasily Vlassov Stein Emil Vollset Theo Vos Kia Vosoughi Giang Thu Vu Isidora S Vujcic Henry Wabinga Tesfahun Mulatu Wachamo Fasil Shiferaw Wagnew Yasir Waheed Fitsum Weldegebreal Girmay Teklay Weldesamuel Tissa Wijeratne Dawit Zewdu Wondafrash Tewodros Eshete Wonde Adam Belay Wondmieneh Hailemariam Mekonnen Workie Rajaram Yadav Abbas Yadegar Ali Yadollahpour Mehdi Yaseri Vahid Yazdi-Feyzabadi Alex Yeshaneh Mohammed Ahmed Yimam Ebrahim M Yimer Engida Yisma Naohiro Yonemoto Mustafa Z Younis Bahman Yousefi Mahmoud Yousefifard Chuanhua Yu Erfan Zabeh Vesna Zadnik Telma Zahirian Moghadam Zoubida Zaidi Mohammad Zamani Hamed Zandian Alireza Zangeneh Leila Zaki Kazem Zendehdel Zerihun Menlkalew Zenebe Taye Abuhay Zewale Arash Ziapour Sanjay Zodpey Christopher J L Murray

JAMA Oncol 2019 12;5(12):1749-1768

Institute for Health Metrics and Evaluation, University of Washington, Seattle.

Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data.

Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning.

Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence.

Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs).

Conclusions And Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.2996DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777271PMC
December 2019

Datasets on organizational citizenship behavior in the selected hospitals with different ownership.

Data Brief 2018 Aug 19;19:288-292. Epub 2018 May 19.

Hospital Administration Research Center, School of Medicine, Sari Branch Islamic Azad University, Sari, Islamic Republic of Iran.

Studying the role of employees as the base of an organization on achieving organizational goals has increased in recent years [1]. To have better organizational citizens, organizations should encourage their staff [2]. As the most powerful form of organizational behavior, organizational citizenship is more influential than organizational cooperation [3]. Studies have shown that cooperative behavior, such as the citizenship behavior results in easier organizational communication, promoting organizational planning, improving inter-personal cooperation and developing better organizational climate, directly influence staff satisfaction, work life quality, service-provision, job commitment and financial output [4]. As the most fundamental organizational behavior, the organizational citizenship behavior (OCB) causes so-called organizational effectiveness. This study Focused on the comparing organizational citizenship behavior components including conscientiousness, courtesy, altruism, sportsmanship and civic virtue among hospitals based on ownership. Research population included all therapeutic and non-therapeutic employees working in the five selected hospital located in Golestan province, Iran in 2016. This study is approved by Ethical committee of Islamic Azad Sari Branch. Based on Cochran׳s sampling formula, 312 employees working in different hospital sections and units (nurses and administrative personnel) were proportionally selected as the research sample. They completed the Persian version of Podsakoff׳s standard scale measuring organizational citizenship behavior. The data were analyzed using SPSS 22 and applying inferential statistics approaches such as t-test, Tukey, and ANOVA in the confidence interval of 95%.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dib.2018.05.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993006PMC
August 2018

Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.

Leuk Res 2018 03 3;66:85-88. Epub 2018 Feb 3.

Hematology-Oncology and Stem Cell Transplantation Research Center/Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Background: Acute promyelocytic leukemia (APL) is a curable form of acute myeloid leukemia; in recent years, the use of new treatment strategies, such as combination therapy, have led to improved APL outcomes. Here, outcomes of patients treated with a combination of arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) are compared against patients treated with single ATO therapy.

Patients And Methods: In total, 67 patients with non-high-risk APL were evaluated. A group of 30 patients received ATO, and another group of 37 patients received ATO plus ATRA. ATO infusion at a dose of 0.15 mg/kg/day was continued till complete remission was achieved or till 60 days of consumption, and after 28 days of rest, second ATO course was initiated for 28 days as consolidation. Four courses separated by 28-day rest were planned. In the second group, 45 mg/m/day ATRA was added to ATO protocol.

Results: All patients except one in the ATO group and all patients in the ATO plus ATRA group were alive after a median follow-up of 18 and 17 months, respectively; 2.5-year overall survival in the ATO group was 86% (p-value = .32). Five patients in the ATO group experienced relapse, and 2.5-year leukemia-free survival in this group was 60%. No relapse occurred in the ATO plus ATRA group (p-value = .01). Differences in the mean of white blood cell (p-value = .67), platelet (p-value = .15), liver (p-value = .37), and renal (p-value = .95) dysfunctions were not significant.

Conclusion: Although ATO has been considered a first-line therapy in patients with APL, several studies have reported improved outcomes with a combination of ATO plus ATRA. This study demonstrated a significant decrease in relapse with this combination compared with single ATO therapy and supported the importance of ATRA in APL treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.01.019DOI Listing
March 2018

Relationship of Employees' Achievement Motivation and Quality of Working Life with Their Self-efficacy at Selected Hospitals with a Multi-group Analysis: Moderating Role of Organizational Ownership.

Mater Sociomed 2017 Dec;29(4):237-241

Social determinants of Health Research Center, Health Research Institute, School of Medicine, Babol University of Medical Sciences, Babol, Iran.

Introduction: Motivational deficiencies and the low quality of working life significantly reduce employees' work performance and consequently their efficacy (effectiveness and proper performance in doing a task or specific tasks).

Aim: The aim of this study was to determine the relationship between achievement motivation and quality of working life with self-efficacy among staff working in Mazandaran hospitals, by taking organizational ownership as a mediator variable.

Materials And Methods: This study was an applied descriptive-correlation. Research population consisted of all staff working in selected hospitals of Mazandaran Province, Iran. 341 employees were selected with randomly-stratified sampling as the statistical sample. Three valid questionnaires were used for data collection. Data were analysis based on structured equations and path analysis with SPSS19 and AMOS.

Results: In private hospitals, there was a significant relationship between the quality of working life and self-efficacy (p<0.001). In relationship between achievement motivation and self-efficacy, there was no significant differences between university hospitals and social security hospitals, but relationship between the quality of working life and self-efficacy was significant (p <0. 05). Considering achievement motivation and self-efficacy in private hospitals and university hospitals, a significant differences was observed (p<0. 05).

Conclusion: The hospital ownership has a moderating in relationship of achievement motivation and quality of working life with self-efficacy. Staff's empowerment courses for university hospitals and improvement in the overall space of job, increase in job security, reducing salary differences is suggested for private hospitals.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5455/msm.2017.29.237-241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723175PMC
December 2017

Liver fibrosis alleviation after co-transplantation of hematopoietic stem cells with mesenchymal stem cells in patients with thalassemia major.

Ann Hematol 2018 Feb 17;97(2):327-334. Epub 2017 Nov 17.

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Kargar Shomali Ave, Shariati Hospital, Tehran, Iran.

The aims of this study are to determine the replacement rate of damaged hepatocytes by donor-derived cells in sex-mismatched recipient patients with thalassemia major and to determine whether co-transplantation of mesenchymal stem cells and hematopoietic stem cells (HSCs) can alleviate liver fibrosis. Ten sex-mismatched donor-recipient pairs who received co-transplantation of HSCs with mesenchymal stem cells were included in our study. Liver biopsy was performed before transplantation. Two other liver biopsies were performed between 2 and 5 years after transplantation. The specimens were studied for the presence of donor-derived epithelial cells or hepatocytes using fluorescence in situ hybridization by X- and Y-centromeric probes and immunohistochemical staining for pancytokeratin, CD45, and a hepatocyte-specific antigen. All sex-mismatched tissue samples demonstrated donor-derived hepatocyte independent of donor gender. XY-positive epithelial cells or hepatocytes accounted for 11 to 25% of the cells in histologic sections of female recipients in the first follow-up. It rose to 47-95% in the second follow-up. Although not statistically significant, four out of ten patients showed signs of improvement in liver fibrosis. Our results showed that co-transplantation of HSC with mesenchymal stem cells increases the rate of replacement of recipient hepatocytes by donor-derived cells and may improve liver fibrosis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3181-9DOI Listing
February 2018

Conjugated Estrogen in Late-Onset Hemorrhagic Cystitis Associated with Hematopoietic Stem Cell Transplantation.

Int J Hematol Oncol Stem Cell Res 2017 Jan;11(1):13-18

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Hemorrhagic cystitis (HC) is one of the most challenging complications in hematopoietic stem cell transplantation (HSCT). Estrogen is one of the suggested treatments for controlling this problem. We performed a randomized case-control study to evaluate the efficacy of oral conjugated estrogen on HC management in 56 HSCT patients. Patients were randomly assigned to the drug group (received 6.25 mg conjugated estrogen oral tablets in a daily single dose during hematuria period) or control group. The median time to complete response was 36 and 24 days in the drug and control group, respectively. The median time of down stage was 24 days in the drug group and 12 days in control group. Adjusted for HC grades, the relative risk of complete response for patients in control group was 1.613 times more than that of patients in drug group; nevertheless, not significant (p=0.122). Our study did not show any benefit in use of oral conjugated estrogen in the management of HC.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338276PMC
January 2017

Self-citation of Medical and Non-medical Universities in Northern Iran.

Acta Inform Med 2016 Dec;24(6):401-404

General Education Department, School of Medicine, Babol University of Medical Sciences, Babol, Iran.

Background: Self-citation is one of the main challenges in the evaluation of researchers' scientific output. This study aimed at comparing the institutional self-citation among the universities located in Northern Iran.

Methods: This study was conducted as a scientometric study. Research population included all scientific productions of 16 Northern Iran Universities with at least 100 indexed documents indexed in the Web of Science (WoS) by 2 June 2015. The citation analysis section of WoS was used for data collection. SPSS was applied for data analysis. Study hypotheses were tested with two independent sample t-test and paired sample t-test.

Results: Producing 16,399 papers, northern Iran universities had 5.33% of contribution in Iran's scientific production. They received 84,058 citations with 17% and 12% of self-citations belonged to the non-medical and medical universities, respectively. Testing hypotheses revealed that increase in received citations significantly increases the rate of self-citation and increase in scientific production does not necessarily increase the rate of self-citation.

Conclusion: The rate of self-citation in the studied universities was not relatively high. However, investigating into the factors affecting the rate of and motives for self-citation needs further research.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5455/aim.2016.24.401-404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203748PMC
December 2016

A Bioinformatics Approach to the Identification of Variants Associated with Type 1 and Type 2 Diabetes Mellitus that Reside in Functionally Validated miRNAs Binding Sites.

Biochem Genet 2016 Jun 28;54(3):211-221. Epub 2016 Jan 28.

Gene Expression - Microarrays Laboratory, Bambino Gesù Children's Hospital, IRCCS, Polo di Ricerca - V.le di San Paolo 15, 00146, Rome, Italy.

The present work is aimed at finding variants associated with Type 1 and Type 2 diabetes mellitus (DM) that reside in functionally validated miRNAs binding sites and that can have a functional role in determining diabetes and related pathologies. Using bioinformatics analyses we obtained a database of validated polymorphic miRNA binding sites which has been intersected with genes related to DM or to variants associated and/or in linkage disequilibrium (LD) with it and is reported in genome-wide association studies (GWAS). The workflow we followed allowed us to find variants associated with DM that also reside in functional miRNA binding sites. These data have been demonstrated to have a functional role by impairing the functions of genes implicated in biological processes linked to DM. In conclusion, our work emphasized the importance of SNPs located in miRNA binding sites. The results discussed in this work may constitute the basis of further works aimed at finding functional candidates and variants affecting protein structure and function, transcription factor binding sites, and non-coding epigenetic variants, contributing to widen the knowledge about the pathogenesis of this important disease.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10528-016-9713-5DOI Listing
June 2016

THE REGRESSION MODEL OF IRAN LIBRARIES ORGANIZATIONAL CLIMATE.

Mater Sociomed 2015 Oct 5;27(5):342-6. Epub 2015 Oct 5.

Health information Management Department, School of Allied Medical Sciences, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran.

Background: The purpose of this study was to drawing a regression model of organizational climate of central libraries of Iran's universities.

Methods: This study is an applied research. The statistical population of this study consisted of 96 employees of the central libraries of Iran's public universities selected among the 117 universities affiliated to the Ministry of Health by Stratified Sampling method (510 people). Climate Qual localized questionnaire was used as research tools. For predicting the organizational climate pattern of the libraries is used from the multivariate linear regression and track diagram.

Results: of the 9 variables affecting organizational climate, 5 variables of innovation, teamwork, customer service, psychological safety and deep diversity play a major role in prediction of the organizational climate of Iran's libraries. The results also indicate that each of these variables with different coefficient have the power to predict organizational climate but the climate score of psychological safety (0.94) plays a very crucial role in predicting the organizational climate. Track diagram showed that five variables of teamwork, customer service, psychological safety, deep diversity and innovation directly effects on the organizational climate variable that contribution of the team work from this influence is more than any other variables.

Conclusions: Of the indicator of the organizational climate of climateQual, the contribution of the team work from this influence is more than any other variables that reinforcement of teamwork in academic libraries can be more effective in improving the organizational climate of this type libraries.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5455/msm.2015.27.342-346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639351PMC
October 2015

Genetic Variants of Cytochrome b-245, Alpha Polypeptide Gene and Premature Acute Myocardial Infarction Risk in an Iranian Population.

J Med Biochem 2015 Oct 19;34(4):402-408. Epub 2015 Sep 19.

Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.

Background: Oxidative stress induced by superoxide anion plays critical roles in the pathogenesis of coronary artery disease (CAD) and hence acute myocardial infarction (AMI). The major source of superoxide production in vascular smooth muscle and endothelial cells is the NADPH oxidase complex. An essential component of this complex is p22phox, that is encoded by the cytochrome b-245, alpha polypeptide (CYBA) gene. The aim of this study was to investigate the association of CYBA variants (rs1049255 and rs4673) and premature acute myocardial infarction risk in an Iranian population.

Methods: The study population consisted of 158 patients under the age of 50 years, with a diagnosis of premature AMI, and 168 age-matched controls with normal coronary angiograms. Genotyping of the polymorphisms was performed by the polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP).

Results: There was no association between the genotypes and allele frequencies of rs4673 polymorphism and premature acute myocardial infarction (>0.05). A significant statistical association was observed between the genotypes distribution of rs1049255 polymorphism and AMI risk (=0.037). Furthermore, the distribution of AA+AG/GG genotypes was found to be statistically significant between the two groups (=0.011).

Conclusions: Our findings indicated that rs1049255 but not rs4673 polymorphism is associated with premature AMI.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2478/jomb-2014-0066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922355PMC
October 2015

Comparison of 60 and 80 mg/m of daunorubicin in induction therapy of acute myeloid leukaemia.

Hematol Oncol 2017 Mar 3;35(1):101-105. Epub 2015 Aug 3.

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the study. Fifty-five patients received 60 mg/m of daunorubicin (arm 1) 1 h IV infusion for 3 days, and the remaining 59 received 80 mg/m (arm 2) 1 h IV infusion for 3 days. Continuous infusion of 100 mg/m /day of cytosine arabinozide IV for 24 h for 7 days was given in both groups. Complete remission rate was 77.78% in group 1 and 76.92% in group 2 (p = 0.92). One-year overall survival was 55.85% [standard error (SE) = 8.05%] in arm 1 and 57.94% (SE = 7.32%) in arm 2. Median follow-up time was 11.1 (SE = 1.43) and 10.28 (SE = 1.29) months, respectively. One-year disease-free survival was 64.41% (SE = 7.39%) in arm 1 and 54.86% (SE = 7.53%) in arm 2. Complete remission, overall survival and disease-free survival were statistically the same in both groups (p = 0.92, 0.697, 0.31). Toxicity and safety profile were similar in two groups but need to transfusion was higher in arm 2. Febrile neutropenia, days of antibiotics consumption and invasive fungal infection prevalence did not show any difference. Mean transfused packed cells and platelets rate were higher in the group that received higher dose of daunorubicin. Considering these results, we found that 60 mg/m of daunorubicin would be more rational and as effective with lower toxicity to 80 mg/m in induction therapy of AML patients at least as scheduled in our trial. Copyright © 2015 John Wiley & Sons, Ltd.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2236DOI Listing
March 2017

The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing Risks.

Int J Hematol Oncol Stem Cell Res 2014 Jul;8(3):1-11

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

The aim of this study was to assess the predictive effect of the EBMT risk score on the outcomes of allogeneic stem cell transplantation in a relatively homogenous group of acute myelogenous leukemia (AML) patients regarding the occurrence of acute and chronic graft versus host disease (GVHD). This historical cohort study included adult patients (≥ 15 years old) with AML (n=363) who received allogeneic peripheral blood stem cell transplantation from HLA-identical sibling donors in the first or higher complete remission following myeloablative conditioning regimens between 2004 and 2011.The patients recruited in this study were followed-up until January 2013. Patients with acute promyelocytic leukemia (APL) were excluded from the study. Early outcomes until day +100 and events after day +100 were regarded for acute and chronic GVHD, respectively. A multi state model for competing risks was applied. We found that the EBMT risk score was a good predictor for overall survival (OS) and relapse incidence; however, it was not associated with transplant-related mortality (TRM). The EBMT risk score was not associated with acute and chronic GVHD. For early outcomes, the predictive effect of the EBMT risk score was not statistically significant in the presence of acute GVHD; however, in the presence of chronic GVHD, it was a significant predictor of relapse but not for TRM. It seems that the effect of EBMT risk score on OS and relapse incidence cannot be affected by GVHD. Although the results were insignificant, there was evidence that the EBMT risk score can predict early outcomes, while for late outcomes, it works well for relapse and OS but not for TRM.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305375PMC
July 2014

Scientific production of Sports Science in Iran: A Scientometric Analysis.

Acta Inform Med 2014 Jun 15;22(3):195-8. Epub 2014 Jun 15.

Sport Management of Shomal University, Amol, Iran.

Background: Physical education and sports science is one of the branches of humanities. The purpose of this study is determining the quantitative and qualitative rate of progress in scientific Production of Iran's researcher in Web of Science.

Methods: Research Methods is Scientometric survey and Statistical Society Includes 233 Documents From 1993 to 2012 are indexed in ISI.

Results: Results showed that the time of this study, Iranian researchers' published 233 documents in this base during this period of time which has been cited 1106(4.76 times on average). The H- index has also been 17. Iran's most scientific productions in sports science realm was indexed in 2010 with 57 documents and the least in 2000.

Conclusions: By considering the numbers of citations and the obtained H- index, it can be said that the quality of Iranian's articles is rather acceptable but in comparison to prestigious universities and large number of professors and university students in this field, the quantity of outputted articles is very low.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5455/aim.2014.22.195-198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130670PMC
June 2014

In silico finding of Putative Cis-Acting Elements for the Tethering of Polycomb Repressive Complex2 in Human Genome.

Bioinformation 2014 23;10(4):187-90. Epub 2014 Apr 23.

Department of Genetics, Shahid Chamran University of Ahvaz, Ahvaz, Iran.

Polycomb Repressive Complex2 maintains a predetermined state of transcription which constitutes a cellular memory stable over many cell divisions. Since this complex acts through the regulation of chromatin structure, it is important to understand how it is recruited to chromatin. The specific target sequences of this complex such as PRE (polycomb repressive element) have not been completely recognized in human genome. In this study, we have compared the target sequences of this complex with non-target genes in tumor cell lines. Through in silico and statistical analyses, we have identified some motifs which are over-represented in target genes against non-target genes. Analyzing these motifs shows some transcription factors which are potential recruiters of Polycomb repressive complex2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.6026/97320630010187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070047PMC
June 2014

Is there association between ABO blood group and the risk factors of unfavorable outcomes of pregnancy?

J Matern Fetal Neonatal Med 2015 Mar 17;28(5):578-82. Epub 2014 Jul 17.

Immunology Research Center, Tabriz University of Medical Sciences , Tabriz , Iran .

There are four major blood groups in human based on the presence of A and B antigens. ABO gene encodes A and B antigens on the surface of red blood cells and there are reported relations between this blood phenotype and pregnancy outcomes in the women. In this study, medical records of 792 healthy pregnant women were investigated and their age and blood test results including blood group with fasting blood sugar, hemoglobin, hematocrit, urea, creatinine and red blood cell counts were analyzed in statistical package for the social sciences. The RBC count in AB blood type was significantly higher than A and O blood group, also FBS level in the people with AB blood group was meaningfully higher than A group. But the mean of HGB and HCT were not significantly different between groups. The serum urea in the AB group was higher than the three other groups and also it was significantly higher in B compared to O and A blood groups. The serum creatinine in the AB group was higher than the three other groups too. Also it was significantly higher in the B group compared to A blood groups. These results indicate that the ABO blood group may have association with some of the risk factors of the unfavorable outcomes of pregnancy and it may be one of the prognostic tools, also it addresses more extensive studies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3109/14767058.2014.927424DOI Listing
March 2015

The outcomes of esophageal and gastric cancer treatments in a retrospective study, single center experience.

Int J Hematol Oncol Stem Cell Res 2014 ;8(2):9-13

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Introduction: Esophageal and gastric cancers are among the most common cancers in Iran. Usually survival of these cases is poor despite of treatment. Here we studied outcome of these cases in our center to have an estimation of general prognosis of patients.

Methods: In this retrospective study, we reviewed the data of patient's files before treatment, including cancer stage at diagnosis, types of treatments and outcomes. We studied 368 patients treated between 1995 and 2011.

Results: The study included 368 patients (248 [67.4%] males and 120 [32.6%] females) with a median age of 58 (range: 23 - 94). Sixty nine patients (18.8%) had esophageal cancer with a median age of 58.5 years (range: 33 - 84), and 47.8% (33/69) of whom were male. Sixty five (17.7%) were reported to have gastro-esophageal junction (GEJ) with a median age of 62.0 (range: 32 - 94), among them 72.3% (47/65) of whom were male and finally Two hundred thirty four (63.6%) had gastric cancer with a median age of 57.0 (range: 23 - 82), which 71.8% (168/234) of whom were male. The Median follow-up was 10 months. The majority of patients were diagnosed at an advanced stage of disease. Stage III or IV was observed in 65.0% (39/60) of patients with esophageal cancer, 75.0% (33/44) with GEJ cancer and 65.4% (121/185) with gastric cancer. In this study, 58% of patients with esophageal cancer, 50.8% with GEJ and gastric cancers had unresectable disease or metastases at presentation. One-year EFS was 51.8% (95% CI: 39.8 - 67.3%), 32.8% (95% CI: 22.1 - 48.7%), and 56.7% (95% CI: 50.1 - 64.3%) in patients with esophageal, GEJ and gastric cancers, respectively (p = 0.002). The 1-year OS was 54.5% (95% CI: 42.6 - 69.8%), 39.5% (95 CI: 28.1 - 55.5%), and 68.2% (95% CI: 61.8 - 75.3%), respectively (p < 0.001).

Conclusion: Cancers of the upper gastrointestinal (GI) tract contribute to the high mortality and morbidity rates because they are more likely to be diagnosed at late or advanced stages of disease. Cancer of the GEJ has a poor prognosis compared to esophageal and gastric cancers. Moreover, treatment protocols may need improvement to achieve better results.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003437PMC
May 2014

The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks.

Int J Hematol Oncol Stem Cell Res 2014 ;8(2):1-8

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Allogeneic Hematopoietic stem cell transplantation (HSCT) is the most effective therapy to prevent relapse in acute lymphocytic leukemia (ALL). This benefit is affected by non-relapse mortality (NRM) due to complications such as graft versus host disease (GVHD). A new approach in analyzing time-dependent covariates in competing risks is landmark analysis. So, the aim of this study is to evaluate the effect of acute and chronic GVHD on long-term outcomes, relapse and NRM, after allogeneic HSCT in adult ALL using landmark analysis. This study was conducted on 252 ALL patients who were allogeneic transplanted from an HLA-identical sibling with peripheral blood (PB) as the source of stem cell from 2004 to 2012 and were followed-up until 2013. In the first 100 days after transplant, a landmark analysis on days +10, +11, +12, +17, +24, and +31 was applied to assess the effect of acute GVHD on early relapse and NRM. Similarly, for patients alive and event-free at day +100 after transplant, a landmark analysis at time points day +101, months +4, +5, +6, +9, and +12 was applied to evaluate the effect of chronic GVHD on late relapse and NRM. Five-year LFS and OS were 35.0% (95% CI: 29.1, 42.2%) and 37.5% (95% CI: 31.3, 45.0%), respectively. Five-year cumulative incidence of relapse was 44.5% (95% CI: 37.9, 51.0%) while this was 20.4% (95% CI: 15.4, 26.0%) for NRM. The landmark analysis in the first 100 days after transplant showed that the grade III/IV of aGVHD has a lower risk of relapse but higher risk of NRM after adjustment for the EBMT risk score. For patients alive at day +100, cGVHD had no significant effect on relapse. Limited cGVHD had lower risk of NRM and after 6 month post-transplant the risk of NRM decreased and there were not important difference between the groups of cGVHD. Using advanced models enables us to estimate the effects more precisely and ultimately make inference more accurately.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003436PMC
May 2014

Twenty years of experience on stem cell transplantation in iran.

Iran Red Crescent Med J 2013 Feb 5;15(2):93-100. Epub 2013 Feb 5.

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.

Background: Hematopoietic stem cell transplantation (HSCT) is a new window to therapy of many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed in the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Sciences. Here we report 20 years experience of HSCT.

Objectives: Our strategy and aim include the protraction of cytogenetic and molecular biological diagnostic tests, the expansion of the first Iranian Cord Blood Bank (ICBB) and development of the first Iranian Stem Cell Donor Program (ISCDP), and improvement the researches in new therapeutic fields.

Patients And Methods: Totally, 3237 patients were undergone HSCT. Of these transplants, 2205 were allogeneic stem cell transplantation, 1016 autologous and 16 syngeneic. Among 2205 patients who were undergone allogenic-HSCT, 34 received cord blood stem cells as stem cell source for transplantation. It is important to point out that cord blood bank at our center provides reliable storage of cord blood stem cells for our patients. Stem cell transplantation was performed for treatment of various diseases such as acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphoblastic leukemia, beta-thalassemia major, sickle- cell thalassemia, sickle- cell disease, multiple myeloma, myelodysplasia, mucopolysaccharidosis, paroxysmal nocturnal hemoglobinuria, non-Hodgkin's lymphoma, Hodgkin's disease, severe aplastic anemia, plasma cell leukemia, Niemann-Pick disease, Fanconi anemia, severe combined immunodeficiency, congenital neutropenia, leukocyte adhesion deficiencies, Chediak-Higashi syndrome, osteopetrosis, histiocytosis X, Hurler syndrome, amyloidosis, systemic sclerosis, breast cancer, Ewing's sarcoma, testicular cancer, germ cell tumors, neuroblastoma, medulloblastoma, renal cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, Wilms' tumor, rhabdomyosarcoma, pancreatoblastoma, and multiple sclerosis. Also, we had 220 cellular therapies for post-myocardial infarction, multiple sclerosis, cirrhosis, head of femur necrosis, Diabetes Mellitus and GvHD treatment. 45 patients were undergone retransplantation in this center.

Results: About 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. Nearly, 21.8% (707) of our patients died after stem cell transplantation. The main causes of death were relapse, infection, hemorrhagic cystitis, graft-versus- host disease and etc.

Conclusions: In Iran, HSCT has been successfully adapted in routine clinical care. Recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5812/ircmj.1915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652510PMC
February 2013

Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience.

J Pediatr Hematol Oncol 2013 Aug;35(6):e239-45

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Background: Hematopoietic stem cell transplantation (HSCT) has been established as a promising treatment in acute myeloid leukaemia (AML). Several studies have been performed to minimize the toxicity of HSCT in children without impairing the efficacy. We report our long-term results of HSCT in pediatric AML patients using non-total body irradiation conditioning regimen.

Procedure: From May 1991 to June 2010, 133 pediatric patients with AML (age<15 y) who were referred to our institute underwent autologous (auto-) or allogeneic (allo-) HSCT. The conditioning regimen consisted of oral busulfan plus etoposide in auto-HSCT patients and oral busulfan plus cyclophosphamide in allo-HSCT patients.

Results: Overall survival (OS), leukemia-free survival (LFS), probability of relapse, and transplantation-related mortality at 3 years were 67.6%, 62.2.5%, 27.3%, and 10.1%, respectively. There was no significant difference between allo-HSCT and auto-HSCT groups. In multivariable analysis using Cox proportional hazards regression model, male sex was associated with significantly improved OS (P<0.001) and LFS (P=0.022). An age ≤3 years was associated with higher relapse (P=0.034) and worse OS (P=0.001) and LFS (P=0.014).

Conclusions: The role of allo-HSCT in pediatric AML patients in first complete remission is uncertain. Further randomized studies are recommended to clarify the optimal postremission therapy in these patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0b013e31827080fcDOI Listing
August 2013

The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.

J Pediatr Hematol Oncol 2012 Mar;34(2):101-7

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

The most widely accepted conditioning regimen to allogeneic hematopoietic stem cell transplantation consists of total body irradiation, especially in patients affected by acute lymphoblastic leukemia (ALL). In this retrospective study, we report our experience on hematopoietic stem cell transplantation in 44 pediatric patients with acute lymphoblastic leukemia using a non-radiation-based conditioning regimen (busulfan/cyclophosphamide). Median age at transplantation was 12.5 years (range, 4 to 14 y). 39 out of 44 patients received transplants in complete remission. At a median follow-up of 390 days, the probabilities of 3-year disease-free survival and overall survival were 50% and 68%, respectively. Disease status of hematopoietic stem cell transplantation was the only significant variable affecting the overall survival. Acute and chronic graft-versus-host disease occurred in 23 (64%) and 12(18%) patients, respectively. Relapse was significantly higher among patients transplanted in advanced disease status. The results of the study indicate that non-radiation-based preparative regimens can be used in pediatric patients with ALL. However, well-designed comparative trials are needed to better clarify the difference between radiation and non-radiation-based conditioning regimens in pediatric ALL.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0b013e31824435a1DOI Listing
March 2012

Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients.

Hematol Oncol Stem Cell Ther 2011 ;4(3):109-15

Hematology, Oncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Background And Objective: Hematopoietic cell transplantation (HCT) is the only therapeutic modality capable of correcting the hematologic manifestations of Fanconi anemia (FA). The development of well-tolerated immunosuppressive conditioning regimens for FA patients undergoing HCT has proven to be a challenging task for hematologists.

Design And Settings: Retrospective, patients referred to the hematology, oncology and stem cell transplantation research center.

Patients And Methods: We analyzed the outcome of 53 FA patients who had undergone HCT between 1992 and 2010. The median age at transplantation was 9 years. Patients received transplants from an HLA-identical sibling (n=39) or matched relative (n=9) and one-antigen locus mismatched other relative/sibling (n=5). All of the patients underwent transplantation with fludarabine and non-fludarabine-based conditioning regimens. No radiation therapy was given.

Results: The median follow-up period for survivors was 13.5 months (range, 3 months-13.5 years). The 3-year overall survival (OS) was 60.6%. The 3-year OS for patients who did or did not receive fludarabine-based preparative regimens for the allograft was 36.4%, and 70%, respectively. However, there were no statistically significant differences in OS rates between these two groups (P=.112). Graft failure occurred in 4 patients (7.5%). All of these 4 patients had received fludarabine-based conditioning regimens. The incidence of acute GVHD after fludarabine-based regimens was 45% versus 79% in non-fludarabine-based regimens (P=.03).

Conclusion: Despite the high incidence of acute GVHD (78.6%) in the non-fludarabine group, which resulted in the death of some patients, the OS rate was significantly better than in fludarabine recipients. Therefore, in spite of the fact that recent studies advocate the fludarabine-based conditioning regimens, we propose to conduct a multicenter, prospective study to evaluate the outcomes of regimens employed in FA patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5144/1658-3876.2011.109DOI Listing
February 2012

Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran.

Arch Iran Med 2011 Sep;14(5):332-4

Hematology Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Background: Acute promyelocytic leukemia is a rare indication for hematopoietic stem cell transplantation. Usually it is indicated as consolidation of salvage regimens following relpase. Here we report our experience with stem cell transplantation in acute promyelocytic leukemia patients.

Methods: Between 1989 and 2011, we performed 40 hematopoietic stem cell transplantation in first complete remission or relapsed acute promyelocytic leukemia patients. Median age of patients was 23.5 years. Patients received 11 autologous and 29 allogeneic hematopoietic stem cell transplantation from their HLA fully-matched sibling donors. Different conditioning regimens were applied. A total of 24 patients received hematopoietic stem cell transplantation who were in first complete remission and the remainder with a second or more complete remission.

Results: Hematopoietic stem cell engraftment was observed in all cases. There were no deaths prior to 100 days after hematopoietic stem cell transplantation. Acute graft versus host disease was mild to moderate in the majority of patients, whereas it was grade III in 4 patients. Chronic graft versus host disease was extensive in 2 cases. With a 4-year median follow up, the relapse rate was 25%. A total of 26 patients are alive. Five year overall survival was 65.5% and 46.8% for allogeneic and autologous hematopoietic stem cell transplantation, respectively.

Conclusion: Hematopoietic stem cell transplantation is an acceptable treatment for acute promyelocytic leukemia. Although there is a statistical difference for overall survival between allogeneic or autologous hematopoietic stem cell transplantation, the choice between autologous or allogeneic transplantation needs to have reliable methods for the detection of molecular remission before hematopoietic stem cell transplantation as well as close, reliable follow up of patients with clinical and molecular parameters.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/008DOI Listing
September 2011